Cellebrite (CLBT) CMO sells 228 shares tied to RSU tax obligations

Rhea-AI Filing Summary

Cellebrite DI Ltd. Chief Marketing Officer David Nicholas Gee reported a small open-market sale of company shares linked to tax obligations from vested equity awards. He sold 228 ordinary shares at a weighted average price of $13.01 per share, with individual trades ranging from $12.84 to $13.175. These shares originated from restricted stock units granted on February 11, 2025 and were sold to cover associated tax liabilities. After the transaction, Gee directly owned 147,705 ordinary shares, indicating that the sale represented only a minor portion of his overall holdings.

Insider Trade Summary

Net Seller: 228 shares ($2,966)

Net Sell 1 txn

Insider GEE DAVID NICHOLAS

Role Chief Marketing Officer

Sold 228 shs ($3K)

Type	Security	Shares	Price	Value
Sale	Ordinary shares, par value NIS 0.00001	228	$13.01	$3K

Holdings After Transaction: Ordinary shares, par value NIS 0.00001 — 147,705 shares (Direct, null)

Footnotes (1)

1. The shares reported as disposed herein were granted on February 11, 2025, in the form of restricted stock units ("RSUs"). The disposition of shares is associated with tax obligations of the reporting person associated with the vesting of the RSUs. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.84 to $13.175, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold: 228 shares Weighted average sale price: $13.01 per share Post-transaction holdings: 147,705 shares +3 more

6 metrics

Shares sold 228 shares Open-market sale on May 12, 2026

Weighted average sale price $13.01 per share Price for 228 ordinary shares sold

Post-transaction holdings 147,705 shares Shares directly owned after reported sale

Price range of trades $12.84–$13.175 Range of individual trade prices within the sale

Net shares sold 228 shares Net-sell direction per transaction summary

RSU grant date February 11, 2025 Grant date of RSUs whose vesting led to sale

Key Terms

restricted stock units ("RSUs"), weighted average price, open-market sale, tax obligations, +1 more

5 terms

restricted stock units ("RSUs") financial

"The shares reported as disposed herein were granted on February 11, 2025, in the form of restricted stock units ("RSUs")."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

tax obligations financial

"The disposition of shares is associated with tax obligations of the reporting person associated with the vesting of the RSUs."

non-derivative financial

""transaction_type": "non-derivative""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GEE DAVID NICHOLAS

(Last) (First) (Middle)

94 SHLOMO SHMELZER ROAD

(Street)

PETAH TIKVA 4970602

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cellebrite DI Ltd. [ CLBT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Marketing Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary shares, par value NIS 0.00001	05/12/2026		S		228(1)	D	$13.01(2)	147,705	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares reported as disposed herein were granted on February 11, 2025, in the form of restricted stock units ("RSUs"). The disposition of shares is associated with tax obligations of the reporting person associated with the vesting of the RSUs.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.84 to $13.175, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ David Gee	05/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Cellebrite (CLBT) report for David Nicholas Gee?

Cellebrite Chief Marketing Officer David Nicholas Gee reported selling 228 ordinary shares. The sale was an open-market transaction tied to tax obligations from vested restricted stock units granted in February 2025, rather than a discretionary reduction of his broader equity position.

How many Cellebrite (CLBT) shares did the CMO sell and at what price?

He sold 228 ordinary shares of Cellebrite at a weighted average price of $13.01 per share. The filing notes multiple trades executed between $12.84 and $13.175, with the detailed breakdown available on request from the company or the SEC staff.

Why were David Nicholas Gee’s Cellebrite (CLBT) shares sold?

The shares sold were associated with tax obligations arising from the vesting of restricted stock units granted on February 11, 2025. This means the transaction was primarily to satisfy tax liabilities tied to compensation, not a strategic change in his long-term investment exposure.

How many Cellebrite (CLBT) shares does the CMO hold after this sale?

Following the sale, David Nicholas Gee directly owned 147,705 ordinary shares of Cellebrite. Compared with the 228 shares sold, this indicates the disclosed transaction affected only a very small fraction of his overall reported equity holdings in the company.

Were the Cellebrite (CLBT) insider share sales part of a broader derivative exercise?

The reported transaction involved non-derivative ordinary shares, not an option or warrant exercise. The filing shows no derivative transactions or remaining derivative positions, and the shares sold came from previously granted restricted stock units that had already vested.